menu
    • menu
    [{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"Bcr\/Abl fusion protein","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"UroGen Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"Balstilimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase II","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tanner Pharma \/ Dompe Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Extractas Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tanner Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Tanner Pharma

    Menu

    Tanner Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botensilimab,Balstilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tanner Expands Botensilimab, Balstilimab Global Access Via Agenus Partnership

                            Details : The partnership aims to grant access to AGEN1181 (botensilimab) & balstilimab. This initiative, delivered via an NPP, offers treatment options for patients with MSS colorectal cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : Botensilimab,Balstilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Elevar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access ...

                            Details : Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types ...

                            Product Name : Apealea

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Elevar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Ascentage Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Named Patient Program for Olverembatinib (HQP1351)

                            Details : Olverembatinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2022

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Ascentage Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : UroGen Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Named Patient Program for Mitomycin for Pyelocalyceal Solution

                            Details : Mitomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 10, 2022

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : UroGen Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tanner Pharma

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Ascentage Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

                            Details : HQP1351 (olverembatinib) is a novel third-generation BCR-ABL inhibitor that can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation, for the treatment of patients with CML intolerant/resistant to at least two TKIs).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 25, 2022

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Ascentage Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

                            Details : The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikista...

                            Product Name : Oxervate

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            July 30, 2020

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea...

                            Details : Under the terms of the agreement, Tanner will be the exclusive supplier of Apealea to health care providers outside of the U.S. on a named patient basis in countries where Apealea is not yet commercially available.

                            Product Name : Apealea

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Extractas Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

                            Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.

                            Product Name : Versacloz

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Extractas Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth